NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
Onco-Innovations Ltd. FAQ: Advancing PNKP Inhibitors for Hard-to-Treat Cancers
Onco-Innovations Ltd. is developing a novel class of DNA damage response therapies called PNKP inhibitors, with lead candidate ONC010, to disrupt cancer cells' DNA repair. The company recently achieved a milestone toward kilogram-scale production of the active pharmaceutical ingredient and signed a Letter of Intent with Nanosoft Polymers to support polymer development and drug delivery optimization.
Onco-Innovations is developing a new class of DNA Damage Response (DDR) therapies, specifically Polynucleotide Kinase Phosphatase (PNKP) inhibitors, designed to disrupt cancer cells' ability to repair DNA damage.
The lead drug candidate is ONC010, a PNKP inhibitor intended to target hard-to-treat cancers by blocking DNA repair in cancer cells.
Onco-Innovations successfully advanced toward kilogram-scale production of the active pharmaceutical ingredient in ONC010, a key step for further development and potential clinical trials.
Cancers often have defective DNA repair, making them vulnerable to further disruption. PNKP inhibitors target a critical enzyme in DNA repair, potentially overwhelming cancer cells' limited repair capacity and leading to cell death.
Onco-Innovations signed a Letter of Intent with Nanosoft Polymers to support polymer development, drug delivery optimization, and formulation work for the ONC010 program.
The latest news and updates relating to ONNVF are available in the company’s newsroom at ibn.fm/ONNVF.
Conventional DNA-damaging therapies like radiation and chemotherapy can kill cancer cells by overwhelming their repair capacity, but some cancers resist these treatments. PNKP inhibitors aim to enhance the effectiveness of such therapies by further disabling repair mechanisms.